Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 56 Results

Title
Intervention Indication Therapeutic Area Year Actions
Lenvatinib and pembrolizumab with transarterial
chemoembolisation for treating hepatocellular
carcinoma
Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Lenvatinib in combination with pembrolizumab for advanced/unresectable hepatocellular carcinoma – first-line Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
Nab-paclitaxel in Combination with Gemcitabine for Resected Pancreatic Ductal Adenocarcinoma - Adjuvant Therapy Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) Pancreatic cancer Gastrointestinal Cancer 2017 View  |  Download
Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Colon cancer Gastrointestinal Cancer 2017 View  |  Download
Nivolumab (Opdivo) for the treatment of Hepatocellular Carcinoma Nivolumab (Opdivo; BMS-936558; ONO-4538) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Nivolumab for hepatocellular carcinoma - adjuvant Nivolumab (Opdivo; BMS-936558; ONO-4538) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2020 View  |  Download
Nivolumab for oesophageal or gastro-oesophageal junction cancer - adjuvant Nivolumab (Opdivo; BMS-936558; ONO-4538) Gastro-oesophageal junction cancer , Oesophageal cancer Gastrointestinal Cancer , Head and Neck Cancer 2019 View  |  Download
Nivolumab in addition to chemotherapy for advanced gastric cancer – first line Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538) Gastric cancer Gastrointestinal Cancer 2018 View  |  Download
Nivolumab in combination with ipilimumab for gastric or gastroesophageal junction cancer – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Gastric cancer Gastrointestinal Cancer 2021 View  |  Download
Nivolumab-ipilimumab for previously untreated advanced hepatocellular carcinoma Nivolumab-ipilimumab Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications